Skip to main content

Table 1 Sorafenib HCC Assessment Randomized Protocol (SHARP) [1] and Asia-Pacific [2] study

From: Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

  SHARP [1]   Asia-Pacific [2]  
Endpoint Sorafenib vs placebo   Sorafenib vs placebo  
  Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
OS 10.7 vs 7.9 months,
0.69 (0.55 to 0.87)
< 0.001 6.5 vs 4.2 months,
0.68 (0.50 to 0.93)
0.014
TTSP 1.08 (0.88 to 1.31) 0.768 0.90 (0.67 to 1.22) 0.50
TTP 5.5 vs 2.8 months,
0.58 (0.45 to 0.74)
< 0.001 2.8 vs 1.4 months,
0.57 (0.42 to 0.79)
< 0.001
RR 2% vs 1%   3.3% vs 1.3%  
  1. OS = overall survival; RR = response rate; TTP = time to tumor progression; TTSP = time to symptomatic progression.
\